Colleen Aldous, Professor for Medical Research, University of KwaZulu-Natal explains how the evidence supporting the use of ivermectin for covid-19 came together to tell a compelling story. In… read more.
When assessing repurposed drugs in a pandemic situation, the totality of evidence should be considered rather than RCTs alone; had this been done the pandemic could have been… read more.
The TOGETHER trial was widely reported as showing that ivermectin was not effective in covid-19, but a straightforward analysis of the results reveals a 59 per cent reduction… read more.
The best time to administer ivermectin is at the beginning of a covid-19 infection so that virus is killed and disease progression averted, according to Colleen Aldous, Professor… read more.
Professor Colleen Aldous is a research professor at the School of Clinical Medicine at the University of Kwazulu-Natal in South Africa. She recently described the SAIVE trial of… read more.
Most symptoms or conditions that develop after mild covid-19 infection linger for several months but return to normal within a year, finds a large study from Israel published… read more.
Global willingness to accept a COVID-19 vaccine increased from 75.2% in 2021 to 79.1% in 2022, according to a new survey of 23 countries that represent more than 60% of… read more.
A three-dose regimen of a whole-parasite vaccine against malaria — called Plasmodium falciparum sporozoite (PfSPZ) vaccine — demonstrated safety and efficacy when tested in adults living in Burkina… read more.
A group of international researchers is calling for revised guidelines to help improve access to hepatitis B treatment in Africa. Hepatitis B is a highly endemic virus in Africa… read more.
Methenamine hippurate could be as effective as antibiotics for preventing recurrent urinary tract infections (UTIs), according to a recent alert from the National Institute for Health and Care… read more.
A recent study provides preliminary evidence of the long-term relationship between prevention and control measures and influenza transmission in China during the COVID-19 pandemic, accounting for the impact… read more.
Molnupiravir (taken as an 800mg dose twice daily for five days) does not reduce hospital admissions or deaths in vaccinated adults with COVID-19 infection who are at higher… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
